Allergy, as one of the worldwide most frequent pathologies, belongs to illnesses with constantly growing incidence among young children. Identification of prognostic markers pointing to increased risk of allergy development, allows introduction of early preventive measures. Probiotic supplementation could be one the preventive measure. It has been shown that introduction of selected probiotic strains or mixtures can prevent development of allergy. In this diploma thesis, the capacity of probiotic strain Escherichia coli O83:K24:H31 (E. coli O83) to support maturation of dendritic cells and polarization of immune responses was tested. Introduction of this probiotic vaccine called Colinfant Newborn appears to be suitable preventive measure, lowering allergy incidence in children with predisposition to development of allergy. The capacity of E. coli O83 to support maturation of the two main subpopulations of dendritic cells (myeloid dendritic cells - mDC and plasmacytoid dendritic cells - pDC) in cord blood of newborns of healthy mothers (children with relatively low risk for allergy development) and allergic mothers (children with relatively high risk for allergy development) was measured by flow cytometry. The presence of cytokines and transcription factors characteristic for particular...

Les cellules dendritiques plasmacytoïdes sont les productrices majeures d’IFN de type I dans l’organisme humain. Durant les infections virales chroniques, telles que l’infection par le Virus de l’Hépatite C, les pDCs sont fonctionnellement altérées. L’efficacité dans plus de 50% des cas du traitement par IFN-α, utilisé jusqu’à récemment, suggère que la modulation de la fonction des pDCs serait une cible intéressante pour le traitement HCV. Les pDCs reconnaissent l’ARN du HCV par les récepteurs Toll-like, et disposent de plus d’un set de récepteurs dits régulateurs qui régulent la production d’IFN-I. L’activation de ces RR inhibe la production d’IFN-I par les pDCs stimulées par les agonistes de TLR7/9. Nous montrons ici que la glycoprotéine d’enveloppe E2 du HCV est un nouveau ligand des RR BDCA2 et DCIR des pDCs, et que cette liaison est responsable de l’inhibition d’IFN-I via l’activation de la voie de signalisation BCR-like. Nous avons ensuite voulu restaurer la production d’IFN-I dans les pDCs en ciblant les kinases décrites de la voie BCR-like, Syk et Mek. En inhibant Syk, l’IFN-I n’a été que partiellement restauré par les concentrations subliminales de l’inhibiteur; les concentrations élevées de cet inhibiteur ont bloqué la production d’IFN-I, suggérant l’implication de Syk dans la voie TLR7/9 comme montré pour l’activation des TLR dans les macrophages. En inhibant MEK, la restauration d’IFN-I est efficace. Les mécanismes de cette restauration sont explorés. Le ciblage pharmacologique de la signalisation BCR-like constituerait une nouvelle approche intéressante pour étudier les mécanismes de modulation de l’activation des pDCs dans les conditions physiopathologiques. / Plasmacytoid dendritic cells are major producers of type I IFN in human organism. During chronic viral infections, such as Hepatitis C Virus infection, pDCs are functionally impaired. More than 50% efficiency of IFN-α treatment, until recently used, suggested that modulation of pDC function could be an important target for HCV treatment. pDCs recognize HCV RNA by Toll-like receptors, and dispose of a set of so-called regulatory receptors that regulate IFN-I production. Crosslinking of these RR such as BDCA-2 and ILT7 has been shown to inhibit IFN-I production by pDCs stimulated with TLR7/9 agonists. In this work we show that HCV envelope glycoprotein E2 is a novel ligand of pDC RR, BDCA-2 and DCIR, and that this binding is responsible for IFN-I inhibition via the activation of the BCR-like pathway. Then we assayed to restore IFN-I in pDCs with crosslinked RR by targeting well-known kinases of BCR-like pathway, Syk and Mek. When inhibiting Syk, IFN-I was only partially restored by subliminal concentrations of Syk inhibitor; high concentrations of Syk inhibitor effectively blocked IFN-I production, suggesting involvement of Syk in the TLR7/9 pathway as it was already demonstrated in TLR activation in macrophages. When inhibiting MEK, the restoration of type I IFN was effective. The underlying mechanisms leading to the restoration are further explored. Pharmacological targeting of BCR-like signaling may constitute an attractive new approach to study mechanisms of modulation of pDC activation in pathophysiological conditions.

Les Cellules Dendritiques sont un groupe hétérogène de cellules présentatrices d’antigènes, importantes pour le contrôle des réponses innées et adaptatives. Les Cellules Dendritiques Plasmacytoïdes (pCD) en représentent une population unique, aux caractéristiques phénotypiques et fonctionnelles particulières, notamment par leur capacité à produire de grande quantité d’Interféron de type I (IFN). Cette signature IFN marque la physiopathologie du Lupus Erythémateux Systémique (LES), maladie auto-immune systémique. Les mécanismes à l’origine de cette production excessive d’IFN par les pCD restent incomplètement élucidés. Nous montrons, dans notre étude, chez l’homme comme dans un modèle murin que les plaquettes, activées dans le LES, participent à la production d’IFN via le CD40L. Cette production en excès d’IFN, a pour conséquence une maturation et activation d’autres Cellules Dendritiques (CD) entrainant l’activation inappropriée des lymphocytes T. Chez le sujet sain, cette activation inappropriée du système immunitaire adaptatif doit être strictement contrôlée afin d’assurer l’homéostasie du système immunitaire. Il a été montré précédemment que de nombreux lymphocytes aux caractéristiques phénotypiques de type mémoire-effecteur (TEM) peuplent les tissus périphériques, notamment le tissu cutané. Ces TEM sont capables de s’activer et proliférer localement en réponse à un stimulus. Les Cellules de Langerhans (LC) sont des cellules dendritiques résidant au niveau cutané dans l’épiderme. Leur fonction est à ce jour l’objet d’une controverse entre une fonction immuno-stimulante (modèle humain) et une fonction immuno-régulatrice (modèle murin). Nous démontrons dans cette étude que les LC, à l’état basal, chez l’homme, induisent la prolifération de Lymphocytes T régulateurs (Treg) au niveau cutané, capables de bloquer la stimulation inappropriée des TEM cutanés. Cependant en présence d’un stimulus infectieux, les LC induisent préférentiellement la prolifération des TEM en limitant celle des Treg. Les LC semblent être à la fois immuno-régulatrices ou stimulantes en fonction du contexte biologique auquel elles sont confrontées. / Dendritic Cell (DC) are a heterogeneous group of antigen-presenting leukocytes that are important in activation of both the innate and adaptative arms of the immune system. Plasmacytoid Dendritic Cells (pDC) represent a unique population, characterized by their ability to produce large amounts of type I Interferon (IFN). This « IFN signature » is a prominent feature of Systemic Lupus disease (SLE). Mechanisms leading to the excessive production of type I IFN remain largely unknown. Here, in our present study, we demonstrate that platelets are activated in SLE patients by circulating immune complexes and represent a major reservoir of CD40L. Activated platelets potentiate the production of type I IFN by pCD through a CD40L/CD40 interaction. Excessive production of type I IFN by pCD leads to DC activation and maturation and inappropriate activation of auto-reactive T cells.Under steady state condition, inappropriate activation of the immune system must be tightly controlled. It has been previously shown that normal adult human skin contains a large number of resident T cells (TRM) expressing the phenotype of Effector Memory T cells (TEM). These TEMTRM are specific for antigens previously encountered through skin and can be activated and proliferate under specific stimulation. Langerhans Cells (LC) are a group of skin resident DC living in epidermis. There is currently substantial controversy regarding the physiologic role of LC with regard to immunoregulation versus immunostimulation. Here we show that under steady state condition, LC induce the proliferation of a small subset of TRM. These proliferating TRM express the phenotype of TREG and are functional. However this stimulation of TREG could be reversed in the presence of foreign antigen in a dose-dependant fashion, as the addition of a pathogen to LC and TRM led to diminished TREG proliferation and increased TEM proliferation. These findings establish a novel immunological role for LC in human skin, allowing for the constitutive maintenance of tolerance, while also permitting the stimulation of resident immune memory in response to infectious challenge

Le neuroblastome (NB) est la tumeur extra-crânienne la plus fréquente du jeune enfant. Malgré une thérapie multimodale très agressive, 40% des patients atteints de NB à haut risque rechutent. Le traitement de ces patients consiste à éliminer la tumeur par chirurgie, radiothérapie et chimiothérapie, à reconstituer la moelle osseuse par une greffe de cellules souches autologues et enfin à éliminer la maladie résiduelle (MRD) par une immunothérapie visant l’antigène GD2 exprimé par les neuroblastes. Notre étude préclinique a examiné l’efficacité de deux stratégies de traitements qui visent à potentialiser les thérapies actuelles et réduire leur toxicité. La première consiste à réduire la masse tumorale par la radiothérapie ciblée combinée à des radiosensibilisants. La deuxième approche est basée sur l’activation des cellules natural killer (NK) pour potentialiser l’effet de l’immunothérapie anti-GD2 et éliminer la MRD. L’autophagie est un processus catabolique qui élimine les protéines et organelles endommagées par différents stress incluant les irradiations. Par conséquent, inhiber l’autophagie pourrait sensibiliser les neuroblastes aux irradiations. Or, nous avons montré qu’étant très radiosensibles, les neuroblastes ne sont pas davantage éliminés par les irradiations quand ils sont traités avec un inhibiteur de l’autophagie. De plus, l’absence d’un inhibiteur efficace de l’autophagie à usage thérapeutique ne permet pas actuellement d’adopter cette approche. Notre étude a également permis de révéler une nouvelle approche de stimulation des cellules NK par les cellules dendritiques plasmacytoïdes (pDC) activées par un ligand du récepteur Toll-like, capable d’éradiquer la MRD et prévenir les rechutes de NB. Nos résultats ont permis, d’une part, d’élucider les mécanismes impliqués dans la lyse des cellules NK activées par les pDC contre les neuroblastes et, d’une autre part, de démontrer que l’axe pDC-NK chez le patient est fonctionnel, augmente l’efficacité de l’anti-GD2 et élimine efficacement les neuroblastes. Ainsi, l’immunothérapie par les cellules NK est une stratégie très prometteuse pour traiter le NB. Cette étude préclinique servira de base à l’élaboration d’un essai clinique pour traiter les enfants atteints de NB au CHU Sainte Justine. / Neuroblastoma (NB) is the most common extracranial solid tumor in childhood. Despite aggressive multimodal therapy, 40% of patients with high-risk NB relapse. The current therapy comprises an induction treatment with chemotherapy and surgery, a consolidation treatment including radiotherapy and high-dose chemotherapy followed by bone marrow rescue with autologous hematopoietic stem cell transplantation and finally anti-GD2 immunotherapy targeting the disialoganglioside (GD2) antigen expressed by neuroblasts to treat minimal residual disease (MRD). Our preclinical study proposes two treatment strategies to potentiate current therapies and reduced toxicities. The first aim to reduce tumor mass by targeted radiotherapy combined with radiosensitizers. The second approach is based on the activation of natural killer (NK) cells to potentiate the effect of anti-GD2 therapy and eliminate MRD. Autophagy is a catabolic process that recycle damaged proteins and organelles, induced under various conditions of cellular stress including irradiation. Therefore, inhibiting autophagy could sensitize neuroblasts to irradiation. However, our study showed that neuroblasts were highly sensitive to irradiation and autophagy inhibitor failed to increase neuroblasts sensitization to irradiation. In addition, the absence of a potent autophagy inhibitor for therapeutic use does not allow this approach to be adopted. Our preclinical study demonstrated a novel approach based on NK cell stimulation with Toll-like activated plasmacytoid dendritic cells (pDC) that enhances the efficacy of anti-GD2 immunotherapy and prevent NB relapse. We elucidated the mechanisms involved in pDC-activated NK cells killing of neuroblasts. We further demonstrated that neuroblasts were efficiently killed by patient’s NK cells after stimulation by activated pDC. This is further increased by the addition of anti-GD2 antibody. Altogether, our study demonstrates that NK cell-based immunotherapy has a real potential to enhance anti-GD2 immunotherapy effect and prevent NB relapse. This preclinical study will serve as a basis for the development of a clinical trial to treat children with NB at CHU Sainte Justine.

Le virus de l’immunodéficience humaine (VIH), responsable du syndrome de l’immunodéficience acquise (SIDA), a touché environ 70 millions d’individus, dont environ la moitié en sont morts. Bien qu’il existe aujourd’hui des traitements efficaces pour prévenir la progression du SIDA, il n’y a actuellement ni vaccin, ni traitement qui ne guérisse complètement. Les cellules dendritiques plasmacytoïdes (pDC) permettent de limiter l’établissement de l’infection en sécrétant des quantités importantes d’interféron de type I (IFN-I) en réponse à la détection du VIH. L’IFN-I permet non seulement d’établir un environnement antiviral, mais aussi d’amorcer la réponse immunitaire innée. Cette réponse des pDCs est régulée notamment par le récepteur immunoglobulin-like transcript 7 (ILT7) dont l’activation par son ligand, bone marrow stromal antigen 2 (BST2), réprime la production d’IFN. BST2 est par ailleurs un facteur de restriction du VIH-1 qui agit en retenant les particules virales à la surface des cellules infectées, limitant ainsi la dissémination du virus. La protéine accessoire Vpu du VIH-1 contrecarre l’action de BST2 sur la relâche virale par une régulation négative des niveaux de surface et par un déplacement hors des sites d’assemblages viraux. Ce déplacement, qui permet l’activation d’ILT7 par BST2, a un rôle double, soit d’augmenter la relâche virale par les cellules infectées, mais aussi de limiter la production d’IFN-I par les pDCs. Par une analyse de variants de Vpu provenant de souches pandémiques et non pandémiques du VIH-1, cette étude indique que cette fonction de Vpu est majoritairement associée au groupe pandémique M avec l’exception notable du sous-groupe C, responsable d’environ la moitié des infections mondiales. Ce phénotype des variants du sous-groupe C est associé à une incapacité à déplacer BST2 dans des cellules T infectées. Des analyses fonctionnelles où des cellules infectées détectées par des pDCs révèlent cependant que les protéines Vpu incapables d’augmenter l’activation d’ILT7 médiée par BST2 ont possiblement développé d’autres mécanismes pour limiter la production d’IFN-I par les pDCs, par exemple la limitation des contacts entre les cellules infectées et les pDCs afin de réduire la détection. / Human immunodeficiency virus (HIV), which is responsible for acquired immune deficiency syndrome (AIDS) has infected over 70 million people, approximately half of which have died from the illness. While there are treatments today that can prevent progression towards AIDS, there is currently no vaccine and no treatment that would completely cure people living with HIV. Plasmacytoid dendritic cells (pDC) limit the establishment of the infection by producing large amounts of type-I IFN (IFN-I) after sensing HIV. IFN-I not only establishes an antiviral environment, but also initiates the innate immune response. This pDC response is regulated, in part, by the pDC-specific receptor immunoglobulin-like transcript 7 (ILT7), which inhibits IFN-I production, upon engagement of its ligand, bone marrow stromal antigen 2 (BST2). BST2 is also an HIV host restriction factor that tethers budding virions at the surface of the infected cell, to limit spread. The HIV-1 accessory protein Vpu counteracts BST2’s restriction through downregulation at the cell surface and displacement away from viral assembly sites. This displacement, which enables ILT7 activation, has a double role: relieving the restriction by BST2 on viral release and repressing IFN-I by pDCs. We screened Vpu variants from pandemic and non-pandemic HIV-1 strains, and found that this function is mostly present in the pandemic group M, although not in variants from clade C which are responsible for half of the global infections. This phenotype in the clade C variants tested was associated with an inability to efficiently displace BST2 in infected T cells. Functional analyses in sensing assays, however, reveal that Vpu variants unable to enhance BST2-mediated ILT7 activation may have evolved compensatory mechanisms to dampen IFN-I production by p

No description available.

Plasmacytoid dendritic cells (pDCs) regulate innate and adaptive immunity. Neurotrophins and their receptors control the function of neuronal tissue. In addition, they have been demonstrated to be part of the immune response but little is known about the effector immune cells involved. We report, for the first time, the expression and immune-regulatory function of the low affinity neurotrophin receptor p75 neurotrophin receptor (p75NTR) by the antigen-presenting pDCs, mediated by toll-like receptor (TLR) 9 activation and differential phosphorylation of interferon regulatory factor 3 and 7. The modulation of p75NTR on pDCs significantly influences disease progression of asthma in an ovalbumin-induced mouse model mediated by the TLR9 signaling pathway. p75NTR activation of pDCs from patients with asthma increased allergen-specific T cell proliferation and cytokine secretion in nerve growth factor concentration-dependent manner. Further, p75NTR activation of pDCs delayed the onset of autoimmune diabetes in RIP-CD80GP mice and aggravated graft-versus-host disease in a xenotransplantation model. Thus, p75NTR signaling on pDCs constitutes a new and critical mechanism connecting neurotrophin signaling and immune response regulation with great therapeutic potential for a variety of immune disorders.

Plasmacytoid dendritic cells (pDCs) regulate innate and adaptive immunity. Neurotrophins and their receptors control the function of neuronal tissue. In addition, they have been demonstrated to be part of the immune response but little is known about the effector immune cells involved. We report, for the first time, the expression and immune-regulatory function of the low affinity neurotrophin receptor p75 neurotrophin receptor (p75NTR) by the antigen-presenting pDCs, mediated by toll-like receptor (TLR) 9 activation and differential phosphorylation of interferon regulatory factor 3 and 7. The modulation of p75NTR on pDCs significantly influences disease progression of asthma in an ovalbumin-induced mouse model mediated by the TLR9 signaling pathway. p75NTR activation of pDCs from patients with asthma increased allergen-specific T cell proliferation and cytokine secretion in nerve growth factor concentration-dependent manner. Further, p75NTR activation of pDCs delayed the onset of autoimmune diabetes in RIP-CD80GP mice and aggravated graft-versus-host disease in a xenotransplantation model. Thus, p75NTR signaling on pDCs constitutes a new and critical mechanism connecting neurotrophin signaling and immune response regulation with great therapeutic potential for a variety of immune disorders.

Plasmacytoid dendritic cells (pDC) represent innate immune cells capable to detect viruses in their endosomal environment via Toll-like receptors (TLRs). Viral nuclear acid recognition leads to the massive production of type I interferon (IFN I) and induction of the antiviral state in uninfected cells. Crosslinking of the surface regulatory receptors, such as BDCA-2, with monoclonal antibodies or with some viruses leads to the activation of MEK1/2- ERK signaling pathway and inhibition of IFN I production in pDC. In this study, the role of MEK1/2 kinase has been highlighted. Its inhibition reversed the inhibitory effect of BDCA-2 crosslinking and its direct activation with PMA led to the inhibition of IFN-α production. Yet an unclear role of pDC in sensing of BK polyomavirus virus (BKV) responsible for kidney transplant rejection was investigated as a major topic of this thesis. Experiments with the pDC cell line Gen2.2 and HRPTEC primary cell line showed that pDCs were not able to detect BKV particles, however, exposure of activated Gen2.2 cells to BKV inoculum dramatically upregulated production of IFN-α. Most importantly, coculture of Gen2.2 cells with BKV- infected HRPTEC cells resulted in IFN-α and TNF-α production, which was prevented by Bafilomycin. These results suggest that BKV-infected...

Plasmacytoid dendritic cells (pDC) are a highly specialized subset of immune cells that sense viral nucleic acids by endosomal toll-like receptors 7 and 9 (TLR7/9). Activation of TLR7/9 leads to the production of type I interferons (IFN-I). Moreover, pDC contribute to the antiviral response by presenting viral antigens to T lymphocytes and link innate and adaptive immunity. pDC need to be properly regulated in order to limit excessive production of IFN-I that is associated with autoimmune diseases. Therefore, pDC possess a battery of regulatory receptors (RR) that limit TLR7/9-mediated cytokine production. This thesis focuses on the mechanism of RR-mediated inhibition of IFN-I production in pDC and explores interactions between pDC and two enveloped viruses, that possess the ability to hijack RR in pDC: hepatitis B virus (HBV) and human immunodeficiency virus (HIV). We showed, that MEK-ERK signaling pathway plays an active role in RR-mediated inhibition of IFN-I in pDC. Our results indicate that in line with other studies of our group, pharmacological targeting of MEK1/2-ERK signaling could be a strategy to re-establish immunogenic activity of pDC. Then, we investigated whether antiretroviral therapy (ART) in a cohort of 21 treatment-naive chronic HIV-infected patients has restored the number and...